M&A Deal Summary |
|
|---|---|
| Date | 2025-08-25 |
| Target | Gilgamesh - Bretisilocin |
| Sector | Life Science |
| Buyer(s) | AbbVie |
| Sellers(s) | Gilgamesh |
| Deal Type | Divestiture |
| Deal Value | 1.2B USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 55,000 |
| Revenue | 56.3B USD (2024) |
AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 15 of 15 |
| Sector: Life Science M&A | 15 of 15 |
| Type: Divestiture M&A Deals | 2 of 2 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 13 of 13 |
| Year: 2025 M&A | 2 of 2 |
| Size (of disclosed) | 8 of 12 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-06-30 |
Capstan
San Diego, California, United States Capstan Therapeutics is developing a targeted delivery platform and therapeutics to reprogram immune cells in vivo for a broad range of disease categories. Capstan was founded in 2021 and is based in San Diego, California. |
Buy | $2.1B |
Gilgamesh is a clinical-stage neuroscience biotech developing innovative, best-in-class new chemical entities that transform the treatment paradigm of psychiatric diseases, moving away from symptom management towards rapid-acting and durable therapies. Gilgamesh designs therapies acting through precedented mechanisms, which are optimized for safety, efficacy, and patient access. Gilgamesh was founded in 2019 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
